StockData

Generate Biomedicines, Inc. (GENB) stock

GENBNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 12, 2026
$10.38+0.54 (+5.49%)

Close on Nov 18, 2026Market cap $1.33BP/E –Yield –

Generate Biomedicines revenue

Revenue is the money a company takes in from selling its products and services, before any costs are deducted.

Quarterly revenue

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q3 FY2026Sep 30, 2026$4.22M-58.3%
Q2 FY2026Jun 30, 2026$6.31M-28.4%
Q1 FY2026Mar 31, 2026$7.22M–
Q3 FY2025Sep 30, 2025$9.63M–
Q2 FY2025Jun 30, 2025$10.13M–
Q1 FY2025Mar 31, 2025$8.82M–

More Generate Biomedicines figures

See a number that looks wrong?